In conclusion, preclinical data and indirect comparison of results across phase 3 RCTs in advanced NPC, ESCC, and NSCLC suggest that toripalimab differentiates itself from other PD-1 inhibitors by providing survival benefit that is relatively independent of tumor PD-L1 expression. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.